Evaluación del Metabolismo Fosfocálcico
Fogiel F, Graffigna M, Salerni H, páginas 161 a 171 del libro “Exploración Funcional Endócrina” del Dr. A. Guitelman y el Dr. S. Aszpis, publicado en marzo de 1992.
Publicaciones de Nuestro Equipo
IGFBP-1: Marcador precoz de Insulinorresistencia en mujeres obesas posmenopausicas.
Belli S, Graffigna M, Oneto A. Revista Argentina de Endocrinología y Metabolismo. 38:191-197, 2001. Con referato.
Efecto del tratamiento hormonal del reemplazo oral sobre las concentraciones sericas de IGF-1, IGFBP-1, IGFBP-3 y Leptina en mujeres posmenopausicas.
Belli S, Oneto A, Graffigna M. Revista Argentina de Endocrinología y Metabolismo. 39: 75-82, 2002. Con referato.
Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.
Pituitary. 2002;5(4):255-60. Guitelman M1, Colombani-Vidal ME, Zylbersztein CC, Fiszlejder L, Zeller M, Levalle O, Scaglia HE.
Retrospective multicentric study of pituitary incidentalomas
Pituitary. 2004;7(3):145-148. doi: 10.1007/s11102-005-1757-1.Day PF1,2, Guitelman M3, Artese R3, Fiszledjer L3, Chervin A3, Vitale NM3, Stalldecker G3, De Miguel V3, Cornaló D3, Alfieri A3, Susana M3, Gil M3.
Effect of ROSIGLITAZONE on insulin resistance, growht factors, and reproductive disturbances in women with polycystic ovary syndrome.
Belli S, Graffigna M, Oneto A, Otero P, Schurman L, Levalle O. Fertility and Sterility. Vol 81 Nº 3: 624-629, 2004
Prevalencia de factores de riesgo cardiovascular en sujetos sanos. Estudio epidemiológico multicéntrico. (Resultados preliminares)
Litwak L.E., Graffigna Mabel Nora, Abdala María Marta., Akel M.E., Aranda C., Gutt Susana, Levalle O., Marcial Toro J., Migliano Mirta, Pérez de la Puente M., Pombo F., Rodríguez Mirta, Scaliter H., Tarruella M.., Yuma M.., Cavallero Elizabeth (†). Revista Argentina de Endocrinología y Metabolismo. Vol 41, Nº 4: 206-213, 2004. Con referato.
Determinación del índice Homa en sujetos presuntamente sanos. Estudio epidemiológico multicéntrico. (Resultados preliminares)
Graffigna Mabel Nora, Litwak L.E., Abdala María Marta., Akel M.E., Aranda C., Gutt Susana, Levalle O., Marcial Toro J., Migliano Mirta, Pérez de la Puente M., Pombo F., Rodríguez Mirta, Scaliter H., Tarruella M.., Yuma M.., Cavallero Elizabeth (†). Revista Argentina de Endocrinología y Metabolismo Vol 42, Nº 1: 12-19, 2005. Con referato.
Caracterísiticas de VLDL Circulante en el Síndrome Metabólico con Esteatosis Hepática (Abstract)
Zago Valeria, Cacciagiú Leonardo, de Larrañaga Gabriela, Graffigna Mabel, Fainboim Hugo, Peres Wingeser Silvia, Belli Susana, Berg Gabriela, Levalle Oscar, Schreier Laura. MEDICINA (Buenos Aires) Vol 66 (Supl II): 84-85, 2006
Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long?
Front Horm Res. 2006;35:88-101.Guitelman M1.
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
Send toJ Clin Endocrinol Metab. 2007 May;92(5):1891-6. Epub 2007 Jan 23.Daly AF1, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabaté MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wémeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montañana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A.
Esteatósis Hepática no alcoholic asociada al Síndrome Metabólico: Relación entre la producción de VLDL y ADIPONECTINA. (Abstract)
Zago V , Cacciagiú L,de Larrañaga G, Gomez Rosso L, Perés Wingeser S, Graffigna M, Belli S, Fainboim H, Brites F, Berg G, Levalle O, Schreier L. MEDICINA (Buenos Aires) Vol 67 (Supl III): 8-32, 2007
The range of normal values of liver enzymes in the era of METABOLIC SYNDROME: The need for a redefinition.
Perés Wingeyer SD, de Larrañaga GF, Belli SH, Graffigna MN, Fainboim H. Eur J Gastroenterol Hepatol. 2008 Jun;20(6):589-591
Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of Metabolic Syndrome.
De Larrañaga G, Wingeyer SP, Graffigna M, Belli S, Bendezu K, Alvarez S, Levalle O, Fainboim H. Clin Appl Thromb Hemost. 2008 Jul;14(3):319-24.
La proteina transportadora del factor de crecimiento insulínico Tipo 1: ¿Un nuevo marcador para la enfermedad hepática grasa no alcohólica?
Mabel Nora Graffigna, Susana H Belli, Gabriela de Larrañaga, Hugo Fainboim, Claudio Estepo, Silvia Peres, Natalia García, Oscar Levalle. Acta Gastroenterológica L Latinoamericana 2009; 39:30-37.
Guía de Práctica Clínica Nacional sobre prevención, diagnóstico y tratamiento de la Diabetes Mellitus Tipo 2.
Para el Primer Nivel de Atención. Ministerio de Salud, República Argentina, 2009.
Tercer consenso argentino sobre patologías endocrinológicas: Diabetes.
Lavalle O, Pusiol E, Sinay I, Alzueta G, Costa Gil J, Dieuzeude G, Faingold C, Graffigna M, Lapertosa S, Libman A, Marcucci G, Mileo Vaglio R, Nader E, Saavedra S, Waitman J. Revista Argentina de Endocrinología y Metabolismo Vol 46, Nº 4: 4-18, 2009.
Relationship between 4G/5G POLYMORPHISM in the PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE and OBESITY in argentinian hispanic adults.
Wingeyer SD, Belli SH, Graffigna MN, Levalle O, de Larrañaga GF. Blood Coagul Fibrinolysis. 2010; 21:196-8.
Síndrome Metabólico y riesgo cardiovascular en estudiantes adolecentes de la Ciudad de Buenos Aires.
Graffigna MN, Honfi M, Soutelo J, Migliano M, Ledesma L, Proietti A, Aranguren M, Pazos M, Musso C, Berg G. Revista Argentina de Endocrinología y Metabolismo 2010, Vol 47, Nº 2: 14-20.
Management of acromegaly in Latin America: expert panel recommendations.
Pituitary. 2010 Jun;13(2):168-75. doi: 10.1007/s11102-009-0206-y Barkan A1, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M.
Endocrine manifestations of Langerhans cell histiocytosis diagnosed in adults.
Pituitary. 2010 Dec;13(4):298-303. doi: 10.1007/s11102-010-0233-8 García Gallo MS1, Martínez MP, Abalovich MS, Gutiérrez S, Guitelman MA.
Experience from the Argentine Pegvisomant Observational Study: preliminary data.
Front Horm Res. 2010;38:42-9. doi: 10.1159/000318493. Epub 2010 Jul 5.García Basavilbaso N1, Guitelman M, Nagelberg A, Stalldecker G, Carabelli A, Bruno O, Danilowitz K, Manavela M, Mallea Gil S, Ballarino C, Guelman R, Katz D, Fidalgo S, Leal R, Fideleff H, Servidio M, Bruera D, Librandi F, Chervin A, Vitale M, Basso A.
Serum insulin-like growth factor-1 measurement in the diagnosis and follow-up of patients with acromegaly: preliminary data.
Front Horm Res. 2010;38:145-51. doi: 10.1159/000318504. Epub 2010 Jul 5.Guitelman M1, Radczuk G, Basavilbaso NG, Oneto A, Basso A.
Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.
Send to. Pituitary. 2010 Dec;13(4):345-50. doi: 10.1007/s11102-010-0243-6.Stalldecker G1, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L, Chervin A, Danilowicz K, Diez S, Fainstein-Day P, García-Basavilbaso N, Glerean M, Gollan V, Katz D, Loto MG, Manavela M, Rogozinski AS, Servidio M, Vitale NM.
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.
J Clin Endocrinol Metab. 2010 Nov;95(11):E373-83. Epub 2010 Aug 4. Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E,Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A.
Marcadores de insulinorresistencia y adiponectina en estudiantes adolecentes con Síndrome Metabólico.
Marcela Aranguren, Adrián Proietti, Jimena Soutelo, Marta Migliano, Margarita Honfi, Carla Musso, Mabel Graffigna, Gabriela Berg . Revista SAD, 2011, Vol. 45 Nro. 1: 8-16
Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to Metabolic Syndrome.
Lucero D, Zago V, López GI, Graffigna M, Fainboim H, Miksztowicz V, Meroño T, Belli S, Levalle O, Wikinski R, Brites F, Berg G, Schreier L. Clin Chim Acta. 2011,412(1-2):143-7. Epub 2010 Sep 29.
Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in Metabolic Syndrome?
Lucero D, Zago V, López GI, Graffigna M, López GH, Fainboim H, Miksztowicz V, Rosso LG, Belli S, Levalle O, Berg G, Brites F, Wikinski R, Schreier L. Clin Chim Acta. 2011, 412(7-8):587-92.
Cardiomatabolic risk factors as APOLIPOPROTEIN B, TRIGLYCERIDE/HDL-CHOLESTEROL RATIO and C-REACTIVE PROTEIN, in adolescents with and without obesity: cross-sectional study in middle class suburban children.
Musso C, Graffigna M, Soutelo J, Honfi M, Ledesma L, Miksztowicz V, Pazos M, Migliano M, Schreier LE, Berg GA. Pediatr Diabetes. 2011, 12(3 Pt 2):229-34.
Role of -675 4G/5G in the PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE and -308G/A TUMOR NECROSIS FACTOR-Α GENE POLYMORPHISMS in obese argentinean patients.
Wingeyer SD, Graffigna MN, Belli SH, Benetucci J, de Larrañaga GF. Genet Test Mol Biomarkers. 2012 May;16(5):372-5
Triglicéridos/HDL- cholsterol ratio: in adolescents without cardiovascular risk factors.
Soutelo J, Graffigna M, Honfi M, Migliano M, Aranguren M, Proietti A , Musso C, Berg G. Archivos Latinoamericanos de Nutrición. 2012, 62 ( 2): 167-171
IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome.
Acta Gastroenterol Latinoam. 2012 Mar;42(1):20-6.Mallea-Gil MS, Ballarino MC, Spiraquis A, Iriarte M, Kura M, Gimenez S, Oneto A, Guitelman M, Machado R, Miguel CM
A 12-month phase 3 study of pasireotide in Cushing's disease.
N Engl J Med. 2012 Mar 8;366(10):914-24. Colao A et al Pasireotide B2305 Study Group.
Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients.
Pituitary. 2012 Dec;15(4):466-71. Boero L, Manavela M, Danilowicz K, Alfieri A, Ballarino MC, Chervin A, García-Basavilbaso N, Glerean M, Guitelman M, Loto MG, Nahmías JA, Rogozinski AS,Servidio M, Vitale NM, Katz D, Fainstein Day P, Stalldecker G, Mallea-Gil MS
Patient-focussed outcomes in acromegaly
Pituitary. 2013 Sep 20.
Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds.
Endocr Relat Cancer. 2012 May 3;19(3):233-41.
Primary empty sella (PES): a review of 175 cases.
Pituitary. 2013 Jun;16(2):270-4.
Association between Β2-ADRENOCEPTOR (ADRB2) HAPLOTYPES and INSULIN RESISTANCE IN PCOS.
Tellechea ML, Muzzio DO, Iglesias Molli AE, Belli SH, Graffigna MN, Levalle OA, Frechtel GD, Cerrone GE. Clin Endocrinol (Oxf). 2013 Apr;78(4):600-6.
Prevalence of cardiovascular risk factors among latin american adolescents: A multilevel analysis.
de Moraes AC, Musso C, Graffigna MN, Soutelo J, Migliano M, Carvalho HB, Berg G. J Hum Hypertens. 2014 Mar;28(3):206-9
High variability in baseline urinary free cortisol values in patients with Cushing's disease.
Send to. Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259. Epub 2013 Jul 15.Petersenn S1, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM; Pasireotide B2305 Study Group.
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. Gadelha MR1, Bronstein MD2, Brue T3, Coculescu M4, Fleseriu M5, Guitelman M6, Pronin V7, Raverot G8, Shimon I9, Lievre KK10, Fleck J10, Aout M10,Pedroncelli AM10, Colao A11; Pasireotide C2402 Study Group.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. Pivonello R1, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. Colao A1, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M;Pasireotide C2305 Study Group.
Patient-focussed outcomes in acromegaly.
Pituitary. 2014 Jan;17 Suppl 1:S18-23. Guitelman M1, Abreu A, Espinosa-de-los-Monteros AL, Mercado M.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1 Schopohl J1, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group.
Reference ranges for an automated chemiluminescent assay for serum insulin-like growth factor I (IGF-I) in a large population of healthy adults from Buenos Aires.
J Endocrinol Invest. 2015 Sep;38(9):951-6. doi: 10.1007/s40618-015-0265-z. Epub 2015 Mar Guitelman M1, Smithuis F, Garcia Basavilbaso N, Aranda C, Fabre B, Oneto A.
Ten years cardiovascular risk estimation according to framingham score and non HDL-CHOLESTEROL in blood donors.
Graffigna MN, Berg G, Migliano M, Salgado P, Soutelo J, Musso C. Diabetes Metab Syndr. 2015 Jan-Mar;9(1):24-7
Sección XIII: HIRSUTISMO IY SÍNDROME DE OVARIO POLIQUÍSTICO: Fisiopatología, diagnóstico y tratamiento.
Belli S, Graffigna MN en FISIOPATOLOGÍA MOLECULAR Y CLÍNICA ENDOCRINOLÓGICA. Dres. Calandra R, Barontini M, Pisarev M, Rey R, Juvenal G. Eli Lilly Interamericana Sucursal Argentina, agosto de 2015
Prolactinomas: evolution after menopause.
Arch Endocrinol Metab. 2016 Feb;60(1):42-6. doi: 10.1590/2359-3997000000138.
Síndrome de Ovario Poliquístico: Fenotipos y enfermedad cardiovascular.
Gamez JM Abruzzese G, Cerrone G, Lioy G, o Mormandi E, Otero P, Belli S, Levalle O, Graffigna MN, Motta A. Rev Argent Endocrinol Metab 2016;53:149-56
Riesgo aumentado de lesiones colónicas preneoplásicas en acromegalia: estudio multicéntrico caso control. Resultados preliminares
Rev argent endocrinol metab. 2017 ;54(4):169–175
Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions.
Endocr Relat Cancer. 2018 May;25(5):L37-L42. doi: 10.1530/ERC-18-0065. Epub 2018 Mar 1Daly AF1, Castermans E2, Oudijk L3, Guitelman MA4, Beckers P5, Potorac I1, Neggers SJCMM6, Sacre N2, van der Lely AJ6, Bours V2, de Herder WW6, Beckers A7.
New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.
Front Endocrinol (Lausanne). 2018 May 24;9:262. doi: 10.3389/fendo.2018.00262. eCollection 2018Fuertes M1, Tkatch J2, Rosmino J2, Nieto L1, Guitelman MA2, Arzt E1,3.
Capítulo Libro - ACROMEGALIA: Aspectos básicos, clínicos y traslacionales .
Moisés Mercado . 2016 Permanyer México , ISBN: 978-84-9926-930-6 Ref.: 2967AX161.Capitulo : Tratamiento Farmacológico : Antagonistas del receptor de hormona de crecimiento.
Principios Fundamentales de Tumores de Hipófisis.
Libro Colaborativo. Coordinadores: Dr. Alberto Chervin y Dr. Marcelo Vitale . Autoras capitulo : Patologìa Hipofisaria y Embarazo ( Guitelman-Tkatch –Garcìa Basavilbaso) (capitulo 11) http://www.virtual.novartis.com.ar/